For instance, Wu and colleagues showed that the use of the FGFR2 inhibitor erdafitinib increased T-cell infiltration in immunocompetent mouse models of triple-negative breast cancer. This evidence concerns the gene FGFR2 and triple-negative breast carcinoma.